Idogen AB (publ)
Board and Advisors | Ambulero
Idogen files patent application for new tolerogenic cell therapy
Idogen's IDO 8 granted orphan drug designation in the USA - Idogen
Iodogen | C16H10Cl4N4O2 | ChemSpider
Idogen aktieägargrupp | Facebook
Idogen - Crunchbase Company Profile & Funding
Idogen - Crunchbase Company Profile & Funding
Idogen's Historical Milestones - Idogen
Nyemission: Idogen förbereder för fas I/IIa-studie Idogen är ett svenskt bioteknikbolag baserat i Lund. Bolaget utvecklar tolerogena cellterapier som gör det möjligt att undvika en oönskad aktivering av kroppens immunsystem. Cellterapin baseras
Investors Home
Idogen AB Interim report Idogen AB Interim report
Idogen AB | Aktiespararna
Idogen's Historical Milestones - Idogen
biotech | pharma | diagnostics | devices
Idogen's cell technology successfully advanced to large-scale production
Idogen presentation - Idogen
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
Idogen - Engineering Immune Tolerance
Idogen AB (publ) Org nr
Redeye-intervju med Idogens VD om emissionsutfallet och rekryteringen av ny CMO - IPO.se
Idogen AB publicerar Årsredovisning för 2018
Idogen appoints Anders Karlsson as new CEO - Idogen
Noteringar i veckan
BioInsights - Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)
Q3 ENG - Idogen
